Navigation Links
CROSSEAL*

ProductsCROSSEAL*
Company Ethicon, Inc.
Item CROSSEAL*
Features 
  • Single tip for drip and spray application
  • No needles
  • Clippable tip with innovative clog-reducing design
  • Preps in less than one minute after thawing
  • Thaws within 10 minutes at 37°C
  • Stable at room temperature for 24 hours
  • Unopened vials can be stored at 2° - 8°C for up to 30 days
  • No mixing required Just follow set-up instructions, then draw the BAC and thrombin into the sterile spray application device, and release the vial connectors
  • Forms an elastic clot that anchors firmly to the bleeding site(s)
  • Transparency allows clear wound examination and tissue visibility
Description CROSSEAL* Fibrin Sealant (Human) achieves a secure clot, targeted to the area of the liver where support for hemostasis is needed, when control of bleeding by conventional surgical techniques, including suture, ligature, and cautery, is ineffective or impractical.

CROSSEAL* Fibrin Sealant (Human) delivers a unique formulation of human Biologically Active Component (BAC) and human thrombin with a high-precision, needle-free application device. It may be sprayed to cover the wound with a transparent layer providing good visualization, and forming an elastic clot.

Info Ethicon, Inc.
Customer Service: (800) 4-ETHICON
Web site: http://www.ethicon.com/

Related medicine products :

1. BUN Liquidplus Reagent
2. Urea Nitrogen (BUN) Liquid Reagent
3. ALT (GPT) Liquidplus Reagent
4. ALT (SGPT) Liquid Reagent (Kinetic Method)
5. g-GT Liquid Reagent
6. Gama-GT Liquid Reagent
7. Inorganic Phosphorus (Liquid)
8. Glucose Color Liquidplus Reagent
9. Glucose UV Liquidplus
10. Glucose Hexokinase Liquid
11. Glucose (Liquid) Reagent
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products:
(Date:8/31/2015)... ... August 31, 2015 , ... CareSource, a nonprofit Ohio-based health ... this capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications ... that have contributed to the company’s rapid growth. As the CareSource business model ...
(Date:8/31/2015)... , ... August 31, 2015 , ... The Bay ... to Veterans residing across southwest Florida by hiring more doctors and nurses and expanding ... of expanded services. , In early July, Dr. Anthony Jabre was selected to lead ...
(Date:8/31/2015)... ... 01, 2015 , ... Neuropsychiatric Disease and Treatment ... transcranial near-infrared laser phototherapy ”. , As corresponding author Dr Theodore Henderson says ... - with mostly palliative treatments only - and now we have shown real ...
(Date:8/31/2015)... ... 31, 2015 , ... Since 1946, the doctors and staff at Clifton Dental ... a patient arrives at the office, the staff will make them feel welcome and ... patient to create a complete dental treatment plan that is unique to each smile! ...
(Date:8/31/2015)... ... ... With the FCPX LUT Soft pack from Pixel Film Studios, editors can quickly and easily ... mathematical formula for modifying an image. The LUT changes every pixel's color to the corresponding ... FCPX LUT Soft requires Final Cut Pro X 10.2 or newer. , By manipulating ...
Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2
... Diffusion,Pharmaceuticals LLC, a clinical-stage drug development company,commercializing ... enhances oxygen diffusion, today announced the results of ... candidate, trans sodium crocetinate (TSC). In,addition, the company ... the proceeds of which will support the company,s ...
... eases the depression that often accompanies the condition, ... -- For rheumatoid arthritis sufferers whose painful illness ... of an age-old technique already embraced by millions ... a half-year exposure to meditation techniques helped patients ...
... Region 5 today told Park Ridge-Niles School District 64,that ... Park,Ridge in mid- September shows no PCB risk to ... the district superintendent, EPA said it had found no,detectable ... and wipe,samples were taken as a precaution because PCBs ...
... Sept. 28 - About a third of American,adults take ... nearly every,case, the goal is better health, even though ... absence of benefit is one thing, but the presence ... of the National Cancer,Institute concluded that there was an ...
... profile of a particular lung tumor can help clinicians ... try first. , A new study led by researchers ... Duke Institute for Genome Sciences & Policy (IGSP) found ... widely used chemotherapy drugs. , We were able ...
... Campaign for Tobacco-Free ... ... V. Corr, Executive Director, Campaign for,Tobacco-Free Kids: Last night, the U.S. ... for a 61-cent-per-pack increase in the,federal cigarette tax to help fund the ...
Cached Medicine News:Health News:Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement 2Health News:Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement 3Health News:Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement 4Health News:Meditation May Help Rheumatoid Arthritis Sufferers 2Health News:Meditation May Help Rheumatoid Arthritis Sufferers 3Health News:Meditation May Help Rheumatoid Arthritis Sufferers 4Health News:EPA Says Follow-Up Sampling Shows No PCB Risk at Park Ridge Elementary School 2Health News:Excessive Multivitamin Use May Raise Risk for Prostate Cancer, from Harvard Men's Health Watch 2Health News:Genomic profiling of lung tumors helps doctors choose most effective treatment 2Health News:Genomic profiling of lung tumors helps doctors choose most effective treatment 3Health News:President Bush Should Protect Kids, Not Big Tobacco By Signing Bill to Increase Cigarette Tax, Fund SCHIP 2
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2